Jiang, Hui-Jie Kang, Chen-Fei Gao, Xiao Chen, Chen Chen, and Qin Zhou. “Folate deficiency and FHIT hypermethylation and HPV 16 infection promote cervical cancerization.” Asian Pacific Journal of Cancer Prevention 15, no. 21 (2014): 9313–9317.
95. Iversen, Lisa, Selvaraj Sivasubramaniam, Amanda J. Lee, Shona Fielding, and Philip C. Hannaford. “Lifetime cancer risk and combined oral contraceptives: the Royal College of General Practitioners’ Oral Contraception Study.” American Journal of Obstetrics and Gynecology 216, no. 6 (2017): 580-e1; Cogliano, Vincent, Yann Grosse, Robert Baan, Kurt Straif, Béatrice Secretan, and Fatiha El Ghissassi. “Carcinogenicity of combined oestrogen-progestagen contraceptives and menopausal treatment.” The Lancet Oncology 6, no. 8 (2005): 552–553; Urban, Margaret, Emily Banks, Sam Egger, Karen Canfell, Dianne O’Connell, Valerie Beral, and Freddy Sitas. “Injectable and oral contraceptive use and cancers of the breast, cervix, ovary, and endometrium in black South African women: case – control study.” PLOS Medicine 9, no. 3 (2012): e1001182: 1–11; Forman, D., T.J. Vincent, and R. Doll. “Cancer of the liver and the use of oral contraceptives.” The BMJ (Clinical Research Edition) 292, no. 6532 (1986): 1357–1361; Henderson, B.E., S. Preston-Martin, H.A. Edmondson, R.L. Peters, and M.C. Pike. “Hepatocellular carcinoma and oral contraceptives.” British Journal of Cancer 48, no. 3 (1983): 437; Bassuk, Shari S., and JoAnn E. Manson. “Oral contraceptives and menopausal hormone therapy: relative and attributable risks of cardiovascular disease, cancer, and other health outcomes.” Annals of Epidemiology 25, no. 3 (2015): 193–200.
96. Gierisch, Jennifer M., Remy R. Coeytaux, Rachel Peragallo Urrutia, Laura J. Havrilesky, Patricia G. Moorman, William J. Lowery, Michaela Dinan et al. “Oral contraceptive use and risk of breast, cervical, colorectal, and endometrial cancers: a systematic review.” Cancer Epidemiology and Prevention Biomarkers (2013): 1931–1943; Bassuk, Shari S., and JoAnn E. Manson. “Oral contraceptives and menopausal hormone therapy: relative and attributable risks of cardiovascular disease, cancer, and other health outcomes.” Annals of Epidemiology 25, no. 3 (2015): 193–200; Fernandez, E., C. La Vecchia, A. Balducci, L. Chatenoud, S. Franceschi, and E. Negri. “Oral contraceptives and colorectal cancer risk: a meta-analysis.” British Journal of Cancer 84, no. 5 (2001): 722–727; Bosetti, Cristina, Francesca Bravi, Eva Negri, and Carlo La Vecchia. “Oral contraceptives and colorectal cancer risk: a systematic review and meta-analysis.” Human Reproduction Update 15, no. 5 (2009): 489–498.
97. Urban, Margaret, Emily Banks, Sam Egger, Karen Canfell, Dianne O’Connell, Valerie Beral, and Freddy Sitas. “Injectable and oral contraceptive use and cancers of the breast, cervix, ovary, and endometrium in black South African women: case-control study.” PLOS Medicine 9, no. 3 (2012): 9; Iversen, Lisa, Selvaraj Sivasubramaniam, Amanda J. Lee, Shona Fielding, and Philip C. Hannaford. “Lifetime cancer risk and combined oral contraceptives: the Royal College of General Practitioners’ Oral Contraception Study.” American Journal of Obstetrics and Gynecology (2017); Grevers, Xin, Anne Grundy, Abbey E. Poirier, Farah Khandwala, Matthew Feldman, Christine M. Friedenreich, and Darren R. Brenner. “Cancer incidence attributable to the use of oral contraceptives and hormone therapy in Alberta in 2012.” CMAJ Open 4, no. 4 (2016): E757–E759.
98. Cogliano, Vincent, Yann Grosse, Robert Baan, Kurt Straif, Béatrice Secretan, and Fatiha El Ghissassi. “Carcinogenicity of combined oestrogen-progestagen contraceptives and menopausal treatment.” The Lancet Oncology 6, no. 8 (2005): 553.
99. Franceschi, Silvia. (2005) “The IARC commitment to cancer prevention: the example of papillomavirus and cervical cancer.” Tumor Prevention and Genetics III. Springer Berlin Heidelberg, 277–297.
100. Там же.
101. Там же, 283.
102. Beral, Valerie, Carol Hermon, Clifford Kay, Philip Hannaford, Sarah Darby, and Gillian Reeves. “Mortality associated with oral contraceptive use: 25 year follow up of cohort of 46 000 women from Royal College of General Practitioners’ oral contraception study.” The BMJ 318, no. 7176 (1999): 99.
103. Maletzky, Barry M., Arthur Tolan, and Bentson McFarland. “The Oregon depo-provera program: a five-year follow-up.” Sexual Abuse: A Journal of Research and Treatment 18, no. 3 (2006): 303–316; Prentky, Robert A. “Arousal reduction in sexual offenders: A review of antiandrogen interventions.” Sexual Abuse: A Journal of Research and Treatment 9, no. 4 (1997): 335–347; Lee, Joo Yong, and Kang Su Cho. “Chemical castration for sexual offenders: physicians’ views.” Journal of Korean Medical Science 28, no. 2 (2013): 171–17; Scott, Charles L., and Trent Holmberg. “Castration of sex offenders: prisoners’ rights versus public safety.” Journal of the American Academy of Psychiatry and the Law 31 (2003): 502–509.
Глава 8
1. Nilsson, Carl Gustaf, Pekka Lähteenmäki, and Tapani Luukkainen. “Levonorgestrel plasma concentrations and hormone profiles after insertion and after one year of treatment with a levonorgestrel-IUD.” Contraception 21, no. 3 (1980): 225–233; Xiao, Bilian, Tao Zeng, Shangchun Wu, Hongzhu Sun, and Na Xiao. “Effect of levonorgestrel-releasing intrauterine device on hormonal profile and menstrual pattern after long-term use.” Contraception 51, no. 6 (1995): 359–365; Jeppsson, S., and E.D.B. Johansson. “Medroxyprogesterone acetate, estradiol, FSH and LH in peripheral blood after intramuscular administration of Depo-Provera to women.” Contraception 14, no. 4 (1976): 461–469; Duijkers, Ingrid J.M., Doris Heger-Mahn, Dominique Drouin, and Sven Skouby. “A randomised study comparing the effect on ovarian activity of a progestogen-only pill (POP) containing desogestrel and a new POP containing drospirenone in a 24/4 regimen.” The European Journal of Contraception & Reproductive Health Care 20, no. 6 (2015): 419–427; Lakha, F., P.C. Ho, Z.M. Van der Spuy, K. Dada, R. Elton, A.F. Glasier, H.O.D. Critchley, A.R.W. Williams, and D.T. Baird. “A novel estrogen-free oral contraceptive pill for women: multicentre, double-blind, randomized controlled trial of mifepristone and progestogen-only pill (levonorgestrel).” Human Reproduction 22, no. 9 (2007): 2428–2436.
2. Nassaralla, Claudia L., Joseph B. Stanford, K. Diane Daly, Mary Schneider, Karen C. Schliep, and Richard J. Fehring. “Characteristics of the menstrual cycle after discontinuation of oral contraceptives.” Journal of Women’s Health 20, no. 2 (2011): 169–177; Jukic, Anne Marie Zaura, Clarice R. Weinberg, Donna D. Baird, and Allen J. Wilcox. “Lifestyle and reproductive factors associated with follicular phase length.” Journal of Women’s Health 16, no. 9 (2007): 1340–1347; Larsson-Cohn, Ulf. “The length of the first three menstrual cycles after combined oral contraceptive treatment.” Acta Obstetricia et Gynecologica Scandinavica 48, no. 3 (1969): 416–422.
3. Gnoth, Christian, P. Frank-Herrmann, A. Schmoll, E. Godehardt, and G. Freundl. “Cycle characteristics after discontinuation of oral
